Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$112.45
▲ $2.77 (+2.5%)
Market data updated: 09/20 04:52 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$12.76B
Day Range
$109.38 - $112.66
52-Week Range
$61.23 - $112.66
Beta
—
Next Earnings
02.11.2026
Support
$73.89
Resistance
$112.66
HALO is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+46.6% (1Y)
Strengths: 19/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 37.6%
Growth
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
67
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $112.45
Evidence: FOMO score jumped from 22 to 56 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
42
Value
45
Momentum
82
Risk
50
Sentiment
100
Fundamental
75
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent coverage of Halozyme Therapeutics centers on investor‑focused events and analyst sentiment. The company is slated to appear at three September healthcare investor conferences, where CEO Dr. Helen Torley and CFO Darren Snellgrove will highlight the commercially validated ENHANZE drug‑delivery platform and an expanding portfolio of delivery technologies. Analysts such as HC Wainwright reaffirm a “Buy” rating with a $115 price target, while performance retrospectives note the stock’s strong ten‑year returns for long‑term investors.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Halozyme Therapeutics, Inc.. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
50
🎯 Conviction (vs. Emotion)
36
Psychology
96
Fundamentals
75
Technical
82
Valuation
45
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+64%
Market Narrative
64
Fundamental Reality
36
Narrative Gap
+28
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
HALO’s market behavior suggests a dominant euphoric state, where extreme outperformance (+42.4% above 200-day average) and perfect sentiment override valuation gaps. Herding is present but muted, as the stock underperformed peers today, signaling selective enthusiasm rather than blind following. The narrative gap (59 vs. 35) hints at overoptimistic expectations, while anchoring near resistance may limit upside. The key question: Will momentum sustain despite the stock’s 7% discount to DCF, or will traders pivot as peers recover?
Updated: 09/09/2026, 05:06 AM
What could change this?
👥 What the crowd believes
"management will discuss its commercially validated ENHANZE platform"
"HC Wainwright & Co. reiterates Halozyme Therapeutics with a Buy and maintains $115 price target"
"Why investing for the long run... could reap huge rewards"
"expanding portfolio of drug delivery technologies"
🧠 Market Brain events driving this
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Philip Fisher — 78/100
🔴 Weakest match
Samuel Armstrong Nelson — 2/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with Philip Fisher standing out as the lone champion, calling it an 'exceptional company quality' pick, while the rest of the crowd either hesitates or outright rejects it. Fisher’s high score reflects his focus on long-term competitive advantages and management excellence, suggesting he’d see deep moats and visionary leadership here. In contrast, market efficiency advocates like Malkiel & Bogle and Graham’s defensive purists dismiss it outright, scoring it poorly because it lacks the statistical cheapness or defensive traits they demand. Meanwhile, cyclical analysts like Nelson and Marks flag overbought conditions or late-cycle risks, while behavioral economists like Mackay and Veblen warn of crowd-driven hype or speculative excess. The middle-ground thinkers—like Housel and Schwager—acknowledge it’s holdable but not effortless, implying it’s a cautious, not aggressive, bet.
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 78
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 69
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 63
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 63
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 49
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 49
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 38
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 37
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 33
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 30
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 27
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 25
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 2
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 2 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
83.6%
Operating Margin
33.2%
Net Margin
22.7%
EBITDA Margin
—
ROE
649.2%
ROA
12.6%
ROIC
—
EPS
$2.64
Cash
$133.82M
Total Debt
$2.14B
Current Ratio
4.66
Debt/Equity
43.89
How is Fair Value calculated? →
Current Price
$112.45
Estimated Fair Value (DCF)
$116.53
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+3.6%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $805.74M | $739.21M |
| 2 | 19.4% | $961.85M | $809.57M |
| 3 | 13.8% | $1.09B | $844.85M |
| 4 | 8.1% | $1.18B | $838.06M |
| 5 | 2.5% | $1.21B | $788.09M |
Base FCF (last actual year)
$644.59M
Terminal Value
$19.12B
Present Value of Terminal Value
$12.43B
Enterprise Value
$16.45B
Net Debt
$2.01B
Equity Value
$14.44B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.41
Tangible Book Value per Share (Tangible NAV)
-$5.81
Sentiment based on basic keywords (not AI) — 10 positive, 10 neutral, 0 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Benzinga · 16.9.2026
Benzinga · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
SeekingAlpha · 15.9.2026
Business Wire · 14.9.2026
Yahoo · 14.9.2026
Investor's Business Daily · 11.9.2026
Yahoo · 11.9.2026
SeekingAlpha · 9.9.2026
ChartMill · 9.9.2026
Yahoo · 4.9.2026
Yahoo · 2.9.2026
StockStory · 2.9.2026
Yahoo · 2.9.2026
Halozyme Therapeutics, Inc. (HALO) currently has a StockIQ AI score of 67/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
HALO currently scores 67/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, HALO's estimated fair value is $116.53, which is 3.6% above the current price of $112.45. This is one valuation model among several signals in the fair-value category, not a price target.
HALO's technical score is 82/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 37.6%; Free cash flow growth: 37.6%; Return on equity (ROE): 649.2% — strong.
Based on the real signals StockIQ computed: Operating margin is eroding over time; Earnings per share (EPS) growth: -25.4%; Net income growth: -28.6%.
StockIQ has no recorded dividend payment history for HALO.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Torley Helen | Open Market Sale | 11.9.2026 | 15,492 | -15,492 | $107.15 |
| Torley Helen | Exercise of Derivative Securities | 11.9.2026 | 20,000 | +20,000 | $18.41 |
| Torley Helen | Exercise of Derivative Securities | 11.9.2026 | 20,000 | -20,000 | $18.41 |
| Torley Helen | Open Market Sale | 11.9.2026 | 4,508 | -4,508 | $107.55 |
| Torley Helen | Open Market Sale | 10.9.2026 | 5,412 | -5,412 | $107.58 |
| Torley Helen | Exercise of Derivative Securities | 10.9.2026 | 20,000 | +20,000 | $18.41 |
| Torley Helen | Open Market Sale | 10.9.2026 | 14,588 | -14,588 | $107.01 |
| Torley Helen | Exercise of Derivative Securities | 10.9.2026 | 20,000 | -20,000 | $18.41 |
| Torley Helen | Exercise of Derivative Securities | 9.9.2026 | 20,000 | -20,000 | $18.41 |
| Torley Helen | Open Market Sale | 9.9.2026 | 13,304 | -13,304 | $107.22 |
| Torley Helen | Exercise of Derivative Securities | 9.9.2026 | 20,000 | +20,000 | $18.41 |
| Torley Helen | Open Market Sale | 9.9.2026 | 100 | -100 | $108.67 |
| Torley Helen | Open Market Sale | 9.9.2026 | 6,596 | -6,596 | $107.82 |
| Appelhans Dannielle | Grant/Award from Employer | 1.9.2026 | 1,778 | +1,778 | — |
| Appelhans Dannielle | Grant/Award from Employer | 1.9.2026 | 1,161 | +1,161 | — |
| Torley Helen | Exercise of Derivative Securities | 19.8.2026 | 20,000 | -20,000 | $18.41 |
| Torley Helen | Open Market Sale | 19.8.2026 | 3,200 | -3,200 | $107.77 |
| Torley Helen | Open Market Sale | 19.8.2026 | 9,600 | -9,600 | $107.22 |
| Torley Helen | Open Market Sale | 19.8.2026 | 7,200 | -7,200 | $106.36 |
| Torley Helen | Exercise of Derivative Securities | 19.8.2026 | 20,000 | +20,000 | $18.41 |
| Torley Helen | Exercise of Derivative Securities | 18.8.2026 | 20,000 | -20,000 | $18.41 |
| Torley Helen | Open Market Sale | 18.8.2026 | 9,400 | -9,400 | $104.87 |
| Torley Helen | Open Market Sale | 18.8.2026 | 4,897 | -4,897 | $104.11 |
| Torley Helen | Open Market Sale | 18.8.2026 | 5,703 | -5,703 | $103.08 |
| Torley Helen | Exercise of Derivative Securities | 18.8.2026 | 20,000 | +20,000 | $18.41 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
14,880,707 shares short as of 2026-08-31 · vs. 14,022,134 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
58.5% of trading volume this week was short selling, vs. 43.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology